Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




FDA Approvals: Aloxi, Levoleucovorin, Arcalyst
Link ID 4327
Title FDA Approvals: Aloxi, Levoleucovorin, Arcalyst
Url http://www.medscape.com/viewarticle/572048?src=rss
Description The FDA has approved palonosetron HCl injection (Aloxi), levoleucovorin injection, and rilonacept injection (Arcalyst). Medscape Medical News
Category Articles > Allergy and Clinical Immunology
Keywords
Date Mar 28, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Allergy and Clinical Immunology
1. A Principled Partnership Between Academic Medicine and Industry
  Darrell G. Kirch, MD, President and CEO, Association of American Medical Colleges, Washington, DC, tells us how medicine and industry can and cannot collaborate.
The Medscape Journal of Medicine
Category:   Articles > Allergy and Clinical Immunology


2. Going Lean in the Emergency Department: A Strategy for Addressing Emergency Department Overcrowding
  Rick G. Kulkarni, MD, Attending Physician, Medical Director, Adult Emergency Department, Yale-New Haven Hospital, describes how to improve emergency department function.
Medscape General Medicine
Category:   Articles > Allergy and Clinical Immunology


3. Albuterol vs Montelukast for Exercise-Induced Bronchospasm in Children: A Best Evidence Review
  This Best Evidence Review weighs in on a study from Pharmacotherapy determining the better choice for preventing exercise-induced asthma. Medscape Family Medicine
Category:   Articles > Allergy and Clinical Immunology


4. Advances in Pemphigus Therapy
  The pemphigus variants represent a group of potentially life-threatening autoimmune mucocutaneous blistering diseases. While systemic corticosteroids remain the treatment of choice for pemphigus, new treatment options are emerging.
Skin Therapy Letter
Category:   Articles > Allergy and Clinical Immunology


5. Brief Noninhaled Intranasal CO2 Relieves Allergic Rhinitis Nasal Symptoms
  Carbon dioxide administered for 60 seconds into each nostril, without inhalation, reduces symptoms of seasonal allergic rhinitis within minutes, with relief lasting for at least 24 hours, a new study shows. Reuters Health Information
Category:   Articles > Allergy and Clinical Immunology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS